• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Triple inhaler reduces COPD flare-ups by 20%

April 5, 2017 By Sarah Faulkner

Triple inhaler reduces COPD flare-ups by 20%Researchers at the University of Manchester found that flare-ups in chronic obstructive pulmonary disease can be reduced by 20% with a combined triple inhaler. The team’s work was published in the Lancet. 

The 2,691-patient trial compared an inhaler that delivers 3 different compounds to a commonly-used inhaler. Another sub-set of patients were administered a triple combination therapy in 2 inhalers.

All of the trial participants were current or former smokers and would expect to experience 1.3 COPD flare-ups per person in a year, according to the researchers. These exacerbations are normally caused by an infection and can result in hospitalization or death.

Instead of the expected 1.3 flare-ups per person each year, the team found that the risk of an exacerbation was lessened by 20% for the group using the triple inhaler.

Using a count of blood eosinophil, the team said it could identify patients more likely to benefit from the triple inhaler containing an inhaled steroid.

“This is the 1st long-term study to look at the possibilities of triple therapy as a preventative measure for COPD exacerbations,” principal investigator Jørgen Vestbo said in prepared remarks. “COPD exacerbations lead to approximately 150,000 hospital admissions and 1.2 million bed-days every year in the UK, so to reduce this figure by 20% would make a huge difference, not only for patients’ quality of life, but also for the resources of the NHS.”

The researchers also noted that the triple inhaler helped improve lung function and resulted in fewer overall symptoms.

The study was funded by the Italian-based company Chiesi Farmaceutica SpA.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Respiratory Tagged With: University of Manchester

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS